Thursday, December 28, 2023 10:30:47 PM
Biotech companies do advanced research studies for their drugs and then apply for FDA approval.
If during the trial phases they get results that are less than expected, the stocks tank, but the company does generally not go out of business. They regroup, redirect and go back to the trial phase. A lot like QSEP makes design and engineering changes before going back out into the field and trying again.
If the biotech company gets good results on ensuing trials, their stock skyrockets. If QSEP gets a contract it would instantly validate the technology and the stock would skyrocket on speculation, simply because of the potential revenue it could generate. Very similar to a biotech company.
Having bad trials or tests are not the end of the line. Biotech cos have proven that. QSEP has indeed proven that over the many years it has continued to survive, much to the chagrin of the bears.
QSEP might just knock the bears out if they get a contract. Wouldn’t that be something ;)
Long.
Recent QSEP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:39:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 01:05:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:52:03 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM